GTL Biotech

GTL Biotech, founded in 2015, is a biotechnology firm specializing in bio-gas to liquid fuel technology licensed from the Massachusetts Institute of Technology (MIT). The company is situated in Yangpu, China. In August 2022, GTL Biotech secured an undisclosed amount in a Seed funding round from Dahe Fortune Cube.

The core of the company's technology involves engineered microorganisms developed through metabolic engineering and synthetic biology. These microbes convert industrial flue gas, which contains carbon dioxide, hydrogen, and carbon monoxide, into high-value products like single-cell proteins and biofuels. This process utilizes fermentation technology to transform low-value industrial off-gas from facilities such as coal plants and steel mills into valuable resources. The technology is designed to be tolerant of impurities like sulfur and NOx, and it operates efficiently at mild temperatures and pressures. The business model focuses on establishing partnerships to create a sustainable ecosystem for food and energy supply.

GTL Biotech also operates as Shaanxi GTL Biotech Co., Ltd, a manufacturer of healthcare ingredients in Xi'an, China. This division supplies a wide range of products including functional food and beverage ingredients, dietary and nutritional supplement ingredients, pharmaceutical ingredients, cosmetic raw materials, and feed additives. The company emphasizes quality control, maintains a stable production capacity, and offers customized solutions, such as formula blending services for its clients. It serves both domestic and international markets, exporting to over 50 countries.

Keywords: bio-gas to liquid fuel, metabolic engineering, synthetic biology, industrial flue gas conversion, single-cell protein, biofuels, fermentation technology, healthcare ingredients, functional food ingredients, cosmetic raw materials, nutritional supplements, pharmaceutical ingredients